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Introduction The protective roles of metallothioneins (MT) against metal toxicity suggest that MT may 
have a functional role in cisplatin resistance. The aim of this study was to investigate the expression of MT 
in specimens of germ cell tumors and compare it with clinical sensitivity to cisplatin based chemotherapy.
Material and methods Tissue blocks of primary GCT specimens obtained from 39 patients were examined 
immunohistochemically for MT expression. Staining intensity was evaluated according to the percentage 
of MT positive cells and graded as [-], [+] and [++]. The staining characteristics were compared with the 
clinical response to chemotherapy.
Results Of the 39 tumors, 3 evidenced no MT expression while 26 and 10 specimens showed [+] and [++] 
staining, respectively. Although seminomas tend to stain weaker than non-seminomas, the difference  
of staining between them was not significant (p = 0.19). Of the 39 patients, 23 underwent cisplatin based 
chemotherapy. Of those, 6 progressed and 17 achieved complete remission. Of the non-responders,  
5 showed [+] and 1 showed [++] staining. Six of the responders showed [+], 10 had [++] and 1 showed  
no staining. No association was found between MT staining and chemo-sensitivity (p = 0.53). 
Conclusions MT expression in primary germ cell tumors did not differ between responding and non-re-
sponding patients and therefore may not be useful in predicting response to chemotherapy.
Corresponding author
Emre Tuzel
Zubeyde Hanim Arastırma 
ve Uygulama Merkezi
6471/5 sk. No. 7 
BÜ Mavisehir plk. Binasi
35550 Izmir, Turkey
phone: +90 23 224 11 000 
1022
emretuzel@gmail.com
Key Words: testicular germ cell tumors ‹› metallothionein ‹› cisplatin ‹› immunohistochemistry  
‹› chemoresistance
Cent European J Urol 2015; 68: 45-50 doi: 10.5173/ceju.2015.01.486
INTRODUCTION
Testicular germ cell tumors (GCT) are particular-
ly interesting from a clinical perspective because 
of their exquisite sensitivity to cisplatin based che-
motherapy. Approximately 80% of patients with ad-
vanced disease can be cured [1]. Despite the clini-
cal efficacy of chemotherapy, resistance remains 
a problem in some patients with GCT. Approxi-
mately 10-20% of patients diagnosed with a GCT 
will not respond to cisplatin based chemotherapy or 
will relapse despite further treatment, representing 
a further challenge for the treating physician [2]. 
The principal cause of therapeutic failures in cases 
of advanced GCTs involves the phenomenon of resis-
tance to cisplatin based chemotherapy.
Metallothioneins (MT) are small, cysteine-rich, met-
al binding proteins which are involved in trace metal 
homeostasis and metabolism, detoxification of toxic 
metals, development of resistance towards metal 
containing drugs and scavenging of free radicals 
[3, 4]. It has been suggested that cellular resistance 
may be mediated by reduced permeability of tumor 
cells to drugs, accelerated DNA repair in cispla-
tin damaged cells and an increase in chemoprotec-
tive thiols including MT [5, 6]. The protective roles 
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of MT against oxidative stress and metal toxicity also 
suggest that MT may have a functional role in cispla-
tin resistance [7]. Experimental studies have shown 
that tumor cell lines with acquired resistance to cy-
totoxic alkylating agents and cisplatin overexpress 
MT [8]. However, the functional roles of MTs in the 
clinical setting are less evident.
In the present study, we examined the expression of 
MT in untreated testicular GCT specimens and com-
pared it with the clinical response to cisplatin based 
chemotherapy in order to investigate the association 
between MT expression and cisplatin resistance.
MATERIAL AND METHOD
The medical records and tumor tissue blocks 
of 39 primary untreated GCT patients who under-
went radical orchiectomy were investigated after 
approval of the study by the local ethics committee 
of our institution. Median age was 25 years (range, 
17-52) and median follow–up was 41 months (range, 
3-156). Tumors were staged according to the Inter-
national Union Against Cancer TNM classification 
and graded according to WHO histopathological 
typing [9, 10]. The histological subtype of the study 
group consisted of 10 seminomas (25.7%), 10 embry-
onal cell carcinomas (25.7%), 3 teratomas (7.6%) and 
16 (41%) mixed GCTs.
Immunohistochemistry
Archival histopathological slides from 39 patients 
which were stained with hematoxylin and eosin (H-E) 
were retrieved and reviewed. The most representa-
tive blocks were selected, cut into 5 µm thick sec-
tions and placed on poly-L-lysine pretreated glass 
slides. Immunohistochemistry was performed using 
the monoclonal primary mouse anti-MT antibody E9 
(Zymed Laboratories, San Francisco, USA), which 
was prepared from immunization of Balb/c mice and 
is able to detect immunreactive MT in formalin fixed 
paraffin embedded human tissues by the streptavi-
din-biotin method (DAKO, LSAB Universal kit, Car-
penteria, USA). Appropriate negative controls were 
obtained by omitting the primary antibody from the 
staining procedure. Human normal testis was used 
as a positive control.
All slides were evaluated twice by pathologists 
on separate occasions without any knowledge of pa-
tients’ clinical outcome. MT staining intensity in the 
tumor samples was evaluated semiquantitatively 
according to the percentage of MT positive cells. 
Tumors with ≥75% staining were classified as show-
ing strong staining and graded as [++], tumors with 
<75% immunostaining were classified as showing 
weak immunostaining and graded as [+] and [-] 
if no immunostaining was observed. The staining 
intensity evaluation has been validated in other tis-
sues as described earlier [11].
Standard chemotherapeutic regimen for patients 
with advanced GCT consisted of 3 or 4 cycles 
of bleomycin, etoposide and cisplatin (BEP). All pa-
tients were re-evaluated after completion of chemo-
therapy. Patients considered as complete responders 
(CR) were those with normal tumor markers and 
no residual mass following chemotherapy, as well 
as patients who had necrosis and fibrosis of mature 
teratoma following post-chemotherapy residual 
mass resection. Patients with 50% or more decrease 
in the diameter of measurable lesions were consid-
ered as partial responders. Patients still having el-
evated levels of tumor markers after chemotherapy 
and patients with persistent vital carcinoma follow-
ing post-chemotherapy residual mass resection were 
considered as non-responders (NR).
The immunostaining characteristics were compared 
with the clinical response in patients who underwent 
cisplatin based chemotherapy. Associations between 
MT expression and the clinicopathological features 
were assessed by the chi-square test. Results were 
considered statistically significant at a p <0.05.
RESULTS
MT staining was heterogenous within each tumor 
and subcellulary MT was localized both in the cyto-
plasm and nucleus in most of the tumor cells. In gen-
eral, cytoplasm stained more frequently and none 
of the tumors showed nuclear staining alone (Figures 
1, 2, 3). Of the 39 tumor samples, 3 (7.7%) evidenced 
no MT expression, while 26 (66.7 %) and 10 (25.6%) 
Figure 1. Seminoma with weak [-] MT immunoreactivity (x 100).
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specimens showed [+] and [++] staining patterns, 
respectively.
The distribution of tumors according to histologic 
subtype and MT expression is listed in Table 1. None 
of the seminomas showed [++] staining. Although 
seminomas tend to stain weaker than non-semino-
mas, the difference of staining intensity between 
these subtypes was not significant. The distribution 
of tumors according to clinical stage and MT stain-
ing intensity is presented in Table 2. Ninety percent 
of tumors with clinical stage I or II disease showed 
MT expression, whereas 100 % of advanced stage tu-
mors showed [+] or [++] staining. No correlation 
was observed between increasing stage in germ cell 
tumors and MT staining intensity (p = 0.09).
None of the patients received radiotherapy or chemo-
therapy before orchiectomy. One patient with advanced 
seminoma (clinical stage III) received cisplatin based 
chemotherapy with [+] MT staining. The patient had 
a complete response following chemotherapy and re-
mained disease free during follow-up. Twenty-two of 
29 patients with non-seminomatous germ cell tumors 
underwent cisplatin based chemotherapy with a me-
dian of 3 (range, 2-8) cycles. Two patients died of pro-
gressive disease, 3 patients had persistently elevated 
tumor markers after chemotherapy and 1 had a vital 
carcinoma following post-chemotherapy residual mass 
excision. These patients were considered as resistant 
to chemotherapy. There was no significant relationship 
between the presence of staining for MT and the re-
sponse to chemotherapy (Table 3) (p = 0.53).
*p=0.09 between seminomas and non-seminomas
CR: Complete responders; NR: non-responders
Table 2. Correlation of clinical staging and MT immunostaining 
of germ cell tumors
Table 1. Distribution of tumors according to histopathological 
subtype and MT expression
Table 3. MT expression and clinical response to cisplatin based 
chemotherapy
MT (%)
Histological subtype n [-] [+] [++] p
Seminoma 10 1 (10) 9 (90) –
0.19
Embryonal carcinoma 10 – 6 (60) 4 (40)
Teratocarcinoma 3 – 3 (100) –
Mixt GCT 16 2 (12.5) 8 (50) 6 (37.5)
MT (%)
[-] [+] [++] p
CR 1 (5.9) 10 (58.8) 6 (35.3)
NR - 5 (83.3) 1 (16.7)
Clinical stage
Tumor histology I II III
Seminoma (n=10)*
MT
[-] 1 (10) – – –
[+] 8 (80) – 1 (10) –
[++] – – – –
Non-seminoma (n=29)
MT
[-] 2 (6.9) – – –
[+] 7 (24.2) 5 (17.2) 4 (13.8) –
[++] 5 (17.2) 2 (6.9) – 4 (13.8)
Figure 2. Embryonal carcinoma showing [=] MT immunoreactivity 
(x 100).
Figure 3. Representative tissue block of an embryonal cell 
carcinoma with intense [++] MT staining (x 100).
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DISCUSSION
The immunohistochemical staining patterns of MT 
have been reported with archival paraffin embed-
ded tumor tissues in various types of human tumors. 
It was suggested that overexpression of MT in ovar-
ian, prostate and colon tumors could have protective 
effects against cisplatin [12, 13, 14], whereas other 
reports did not support this perception [15].
A number of in vitro experimental studies have 
shown that tumor cell lines with acquired resistance 
to cisplatin overexpress MT [8, 16]. However, other 
investigators have reported an inverse correlation 
between resistance and MT or total amount of sul-
phydryl groups both in cell lines and clinical samples 
[17, 18]. For instance, Masters et al. reported high 
MT levels in cisplatin sensitive testicular tumor cell 
lines [19]. Thus, experimental evidence suggesting 
a role of MT in cisplatin resistance appears to be in-
conclusive.
The importance of MT in human GCT has been ex-
amined clinically in 4 previous studies. However, 
the data on the predictive value of MT expression 
regarding cisplatin resistance has been divergent 
[18, 20, 21,22]. In a previous study, the intensity 
and extent of MT staining assessed in tissue sections 
of 9 embryonal cell carcinomas. The authors ob-
served a considerable heterogeneity in the MT con-
tent among individual cells and proposed that MT 
may be considered as an onco-developmental prod-
uct [23]. The same investigators later assessed the 
degree of MT immunostaining in 33 primary testicu-
lar GCT specimens [20]. They noted a distinct differ-
ence between MT staining in seminomas and non-
seminomas. Non-seminomas tended to stain heavily 
for MT, especially in the more advanced stages [20]. 
Three patients with advanced seminoma and 15 
of 23 patients with non-seminomatous testis tumors 
received cisplatin based chemotherapy. Tumors from 
2 patients presented with a complete response. One 
of the two patients died due to progressive disease 
during initial chemotherapy and 2 patients with re-
sistance to first line chemotherapy were reported 
to show heavy MT staining [20]. In that study, al-
though a direct correlation between cisplatin re-
sistance and MT content had not been established, 
the authors highlighted the possibility of such a re-
lationship depending on inferential clinical data. 
In contrast, in 77 patients with germ cell testicular 
tumors, high MT immunostaining was found to pre-
dict a better response rate to chemotherapy, oppos-
ing the hypothesis that MT over-expression contrib-
utes to cisplatin resistance in this tumor type [21]. 
The authors attributed these discrepancies to the 
immunohistochemical staining techniques. More-
over, an intense MT staining in 85% of seminomas 
was observed and 78% of poor responders to chemo-
therapy showed no or little staining for MT (all with 
non-seminomas of advanced stage) [21]. According 
to these findings, authors suggested that MT expres-
sion might be a marker of chemo-sensitivity and its 
absence, when it occurs, indicated a resistant tumor 
type [21].
Meijer et al. investigated MT levels and functional-
ity both in the cell line model and in 14 specimens 
of human GCT, as well as in post-chemotherapy re-
sidual vital GCT [18]. Metallothionein levels of cell 
lines were found to be inversely correlated with sen-
sitivity to cisplatin. In agreement with the in vitro 
data, immunohistochemical detection of MT was re-
ported to be high in 11/14 primary human germ cell 
tumors. No difference was documented in MT pro-
tein expression between primary GCT of responding 
(n = 6) or non-responding (n = 8) tumors to cispla-
tin based chemotherapy [18]. Interestingly, all post-
chemotherapy residual vital GCTs tested showed 
a decreased or undetectable level of MT expression 
compared with their primary tumors. This finding 
attributed to the tissue specific expression of MT iso-
forms [18]. The authors concluded that MT expres-
sion in primary GCTs did not discriminate between 
responding and non-responding patients, and there-
fore could not be used to predict response to chemo-
therapy [18].
In another study, the immunohistochemical stain-
ing pattern of proteins involved in the regulation 
of apoptosis, cell cycle control, and drug export and 
inactivation were investigated in samples of un-
selected GCTs (n = 20) in patients achieving a com-
plete remission following chemotherapy (n = 12) and 
in chemotherapy refractory patients (n = 24) [22]. 
Mature teratoma components (n = 10) within tumor 
samples from all groups were analyzed separately. 
Metallothionein immunostaining was identified 
in 35%, 58% and 45% of unselected GCTs, chemo-
therapy responsive tumors and chemotherapy re-
fractory tumors, respectively [22]. In that study, 
no significant difference was observed in any of the 
potential regulators of chemotherapy sensitivity, 
including MTs, between the samples of responding 
or chemotherapy refractory tumors. Because MT 
was detectable in tumors regardless of treatment 
outcome or histology, the authors suggested that the 
presence of MT immunostaining was not sufficient 
to confer resistance [22].
In the present study, we examined the immunuhis-
tochemical expression pattern of MT in a cohort 
of testis tumor patients and also focused explicitly 
on the implications of MT overexpression in the sub-
group of patients who received cisplatin based che-
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of resistance to cisplatin. In addition, the contro-
versial results of the previous studies could possibly 
be attributed to the methods applied using antibodies 
that were unable to distinguish specific MT isoforms, 
metal bound and metal free forms of the protein [4]. 
Subcellular distribution of MT differs between cell 
types and this may be more important than MT lev-
els in cellular protection against cisplatin damage.
The low number of patients may be considered the lim-
iting factor for the power of the present study. In par-
ticular, the lack of statistical significance between the 
groups in the present study might be attributed to the 
inclusion of limited number of patients. Further stud-
ies including larger number of patients are warranted 
to overcome this ubiquitous problem.
CONCLUSIONS
MT expression in primary germ cell tumors did not 
differ between responding and non-responding pa-
tients and therefore may not be useful in predicting 
response to chemotherapy. Constitutive expression 
of MT does not seem to depend on the phenotype 
of the tumor, and mechanisms of drug resistance 
in primary testicular germ cell tumors is probably 
multifactorial. Further research is required to inves-
tigate the molecular mechanisms behind the resis-
tance of cisplatin in GCT.
motherapy. Despite the findings of Eid et al., who 
reported that MT overexpression in GCT indicates 
a favorable response to cisplatin therapy, no such 
relationship was detected in our patient popula-
tion using monoclonal antibody E9. Consistent with 
the findings of three previous studies [20, 21, 22], 
we found no significant association between overex-
pression of MT and sensitivity to cisplatin based che-
motherapy. In the present series, of the 23 patients 
receiving cisplatin based chemotherapy, 17 achieved 
a complete response. Of those, 16 (94 %) showed 
weak or strong MT staining and all of the non-re-
sponders showed [+] or [++] MT staining. On the 
other hand, it is noteworthy that all of the patients 
who failed to achieve a complete response follow-
ing cisplatin based chemotherapy had some degree 
of MT staining. The process of cisplatin resistance 
is determined by multiple factors on different cellu-
lar levels, such as changes in cellular drug uptake 
and efflux, leading to decreased drug accumulation 
[24]. Nevertheless, a direct measure of the correla-
tion between cisplatin resistance and MT content 
in tumors may be obscured by the complexity of cel-
lular defenses against toxicity. Furthermore, genetic 
variability of the patients themselves might also af-
fect the expression of MT or sensitivity to cisplatin. 
It appears that in human GCTs, MT may be associ-
ated, but is certainly not required, for the induction 
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